Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 21, 2013

View Archived Issues

Jazz Pharmaceuticals presents company outlook

Discovery of novel dual NK1 receptor antagonist/SERT inhibitor for the treatment of depression

International Stem Cell tests its hpSC-derived hepatocytes in vivo

Bosutinib receives positive CHMP opinion for conditional marketing authorization

CHMP recommends approval of Jetrea in Europe for vitreomacular traction

Novel antibacterials created by Kyorin and Merck & Co.

YH-GKA identified as a novel glucokinase activator for treating diabetes

New HDAC6 inhibitors designed at U.S. institutes

Researchers design a gene knockout mouse using TALEN-mediated mutagenesis in zygotes

State University of New Jersey patents novel RNA polymerase bipartite inhibitors

Research at Myrexis yields new NAmPRTase inhibitors

Research at Roche and Genentech disclose novel PC9-binding peptides

University of Pittsburgh designs novel H1N1 influenza vaccines

Serina Therapeutics partners with AstraZeneca

Cancer Research UK and AstraZeneca begin clinical development of AZD-0424

Hexal presents new prodrugs of cilazapril

FDA approves Botox for overactive bladder

EMA confirms recommendation to suspend nicotinic acid/laropiprant

Roche presents new HCV therapeutics

Recordati completes acquisition of certain Lundbeck products

Phase II trial of ponatinib in squamous cell lung cancer begins

Popular Stories

NIH changes set industry up for workforce, ideas drought
BioWorld
On March 1, 2025, former NIH director Francis Collins’ announced that he had fully resigned from the NIH, where he continued to lead a laboratory after his...
Today's news in brief
BioWorld
BioWorld briefs for March 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for March 12, 2025
At CROI, HIV cure trials raise hopes for broader applicability
BioWorld
At the 2025 meeting of the Conference on Retroviruses and Opportunistic Infections (CROI) it was the best of times, it was the worst of times. On the first full...
Hummingbird migrates ADCs, tech to newco Callio’s $187M debut
BioWorld
Antibody-drug conjugate (ADC)-focused Callio Therapeutics debuted on March 3 with the closing of a $187 million series A financing round based on cancer drug...